134th ENMC international workshop: Outcome measures and treatment of spinal muscular atrophy 11-13 February 2005 Naarden, the Netherlands

Neuromuscular Disorders

Volumn 15, Issue 11, 2005, Pages 802-816

  Bertini, E ^a   Burghes, A ^a   Bushby, K ^a   Estournet Mathiaud, B ^a   Finkel, R S ^a   Hughes, R A C ^a   Iannaccone, S T ^a   Melki, J ^a   Mercuri, E ^a   Muntoni, F ^a   Voit, T ^a   Reitter, B ^a   Swoboda, K J ^a   Tiziano, D ^a   Tizzano, E ^a   Topaloglu, H ^a   Wirth, B ^a   Zerres, K ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; GABAPENTIN; HYDROXYUREA; LEVACECARNINE; PLACEBO; RILUZOLE; VALPROIC ACID;

BREATHING MUSCLE; BULBAR PARALYSIS; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DISEASE CLASSIFICATION; GASTROESOPHAGEAL REFLUX; GENETIC PREDISPOSITION; HUMAN; MUSCLE WEAKNESS; NETHERLANDS; PATHOGENESIS; PHYSIOTHERAPY; PRIORITY JOURNAL; PROFESSIONAL DELEGATION; PROFESSIONAL PRACTICE; RASH; RESPIRATORY FAILURE; SCOLIOSIS; SPINAL MUSCULAR ATROPHY;

ANIMALS; HUMANS; MUSCULAR ATROPHY, SPINAL; NETHERLANDS; TREATMENT OUTCOME;

EID: 26944503463     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2005.07.005     Document Type: Conference Paper

References (59)

1. Crawford TO. Concerns about the design of clinical trials for spinal muscular atrophy. Neuromuscul Disord 2004;14: 456-60. Review.
2. C.L. Lorson, J. Strasswimmer, and J.M. Yao SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet 19 1998 63 66
3. M. Feldkotter, V. Schwarzer, R. Wirth, T.F. Wienker, and B. Wirth Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy Am J Hum Genet 70 2002 358 368
4. C. Helmken, Y. Hofmann, and F. Schoenen Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1 Hum Genet 114 2003 11 21
5. Lorson CL, Androphy EJ. 2000. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 9:259-265.
6. UR Monani Sendtner M, Coovert DD, et al. Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons? Hum Mol Genet 11 2002 93 105
7. S. Jablonka, M. Bandilla, and S. Wiese Co-regulation of survival of motor neuron (SMN) protein and its interactor SIP1 during development and in spinal muscular atrophy Hum Mol Genet 10 2001 497 505
8. L. Fan, and LR Simard Survival motor neuron (SMN) protein: role in neurite outgrowth and neuromuscular maturation during neuronal differentiation and development. Hum Mol Genet 11 2002 1605 1614
9. HL Zhang, F Pan, B Hong, SM Shenoy, RH Singer, and GJ Bassell Active transport of the survival motor neuron (SMN) protein and the role of exon-7 in cytoplasmic localization. J Neurosci 23 2003 6627 6637
10. H. Hsieh-Li, JG Chang, and Y-J Jong A mouse model for spinal muscular atrophy. Nat Genet 24 2000 66 70
11. U.R. Monani, M. Sendtner, and D.D. Coovert The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 9 2000 333 339
12. S Baron-Delage Abadie A, Echaniz-Laguna A, Melki J, Beretta L. Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol Med 6 2000 957 968
13. CJ Andreassi Jarecki J, Zhou DD, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 10 2001 2841 2849
14. J.G. Chang, HM Hsieh-Li, YJ Jong, NM Wang, and CH Tsai Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 98 2001 9808 9813
15. ML Zhang, CL Lorson, and EJ Androphy Zhou J. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther 8 2001 1532 1538
16. M.L. McWhorter, U.R. Monani, A.H. Burghes, and C.E. Beattie Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding J Cell Biol 162 2003 919 931
17. Le TT, Pham LT, Butchbach ME, et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 2005; 14: 845-57.
18. MER Butchbach Le TT, Burghes AHM. Protective effects of butyrate analoguesand prodrugs on a mouse model for spinal muscular atrophy. Abstract 226.17 Neuroscience meeting, S. Diego, USA October 23 2004 27
19. M Azzouz Le T, Ralph GS, et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 114 2004 1726 1731
20. L Cartegni, and AR Krainer Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 Nat Genet 30 2002 377 384
21. C. Helmken, Y. Hofmann, and F. Schoenen Evidence for a modifying pathway in SMA discordant families: Reduced SMN levels decreases the amount of its interacting partners and of Htra2-beta1 Hum Genet 114 2003 11 21
22. L. Brichta, Y. Hofmann, and E. Hahnen Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy Hum Mol Genet 12 2003 2481 2489
23. C.J. Sumner, T.N. Huynh, and J.A. Markowitz Valproic acid increases SMN levels in spinal muscular atrophy patient cells Ann Neurol 54 2003 647 654
24. C. Andreassi, C. Angelozzi, and F.D. Tiziano Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy Eur J Hum Genet 12 2004 59 65
25. C. Brahe, T. Vitali, and F.D. Tiziano Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients Eur J Hum Genet 13 2005 256 259
26. C. Cifuentes-Diaz, S. Nicole, and M.E. Velasco Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model Hum Mol Genet 11 2002 1439 1447
27. F. Wahl, E. Renou, V. Mary, and J.M. Stutzmann Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury Brain Res 756 1997 247 255
28. R. Katoh-Semba, T. Asano, and H. Ueda Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus FASEB J 16 2002 1328 1330
29. H. Haddad, C. Cifuentes-Diaz, A. Miroglio, N. Roblot, V. Joshi, and J. Melki Riluzole attenuates spinal muscular atrophy disease progression in a mouse model Muscle Nerve 28 2003 432 437
30. J.C. Lesbordes, C. Cifuentes-Diaz, and A. Miroglio Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy Hum Mol Genet 12 2003 1233 1239
31. S. Nicole, B. Desforges, and G. Millet Intact satellite cells lead to remarkable protection against Smn gene defect in differentiated skeletal muscle J Cell Biol 161 2003 571 582
32. C. Soler-Botija, I. Ferrer, I. Gich, M. Baiget, and E.F. Tizzano Neuronal death is enhanced and begins during fetal development in type I spinal muscular atrophy spinal cord Brain 125 2002 1624 1634
33. A. Fidzianska, and J. Rafalowska Motor neuron death in normal and spinal muscular atrophy-affected human fetuses Acta Neuropathol 104 2002 363 368
34. C. Soler-Botija, I. Ferrer, J.L. Alvarez, M. Baiget, and E.F. Tizzano Downregulation of Bcl-2 proteins in type I SMA motor neurons during fetal development J Neuropathol Exp Neurol 62 2003 420 426
35. C. Soler-Botija, I. Cuscó, and E. López Choline acetyltransferase expression does not identify early pathogenic events in fetal SMA spinal cord Neuromusc Disord 15 2005 253 258
36. C. Soler-Botija, I. Cuscó, L. Caselles, E. López, M. Baiget, and E.F. Tizzano Implication of fetal SMN2 expression in type I SMA pathogenesis: protection or pathological gain of function? J Neuropathol Exp Neurol 64 2005 215 223
37. B.S. Russman, C.R. Buncher, M. White, F.J. Samaha, and S.T. Iannaccone Function changes in spinal muscular atrophy II and III The DCN/SMA Group. Neurology 47 1996 973 976
38. B.S. Russman, S.T. Iannaccone, and F.J. Samaha A phase 1 trial of riluzole in spinal muscular atrophy Arch Neurol 60 2003 1601 1603
39. R.G. Miller, D.H. Moore, and V. Dronsky A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 191 2001 127 131
40. L. Merlini, A. Solari, and G. Vita Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study J Child Neurol 18 2003 537 541
41. E. Mercuri, E. Bertini, and S. Messina Pilot trial of phenylbutyrate in spinal muscular atrophy Neuromuscul Disord 14 2004 130 135
42. M. Main, H. Kairon, E. Mercuri, and F. Muntoni The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation Eur J Paediatr Neurol 7 2003 155 159
43. S.T. Iannacone, and L.S Hynan AmSMART Group Reliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol 60 2003 1130 1136
44. J.R. Bach, J.S. Baird, D. Plosky, J. Navado, and B. Weaver Spinal muscular atrophy type 1: management and outcomes Pediatr Pulmonol 34 2002 16 22
45. U. Mellies, C. Dohna-Schwake, F. Stehling, and T. Voit Sleep disordered breathing in spinal muscular atrophy Neuromuscul Disord 14 2004 797 803
46. C. Ioos, D. Leclair-Richard, S. Mrad, A. Barois, and B. Estournet-Mathiaud Respiratory capacity course in patients with infantile spinal muscular atrophy Chest 126 2004 831 837
47. Finkel RS, Bönnemann CG, Weinerb DJ, et al. Defining outcome measures for clinical trials in spinal muscular atrophy, type 1. Neuromuscul Disord 2004;14:596:Abst. T.P.2.03.
48. M.B. Bromberg, and K.J. Swoboda Motor unit number estimation in infants and children with spinal muscular atrophy Muscle Nerve 25 2002 445 447
49. ST Iannacone AmSMART Group Outcome measures for pediatric spinal muscular atrophy. Arch Neurol 59 2002 1445 1450
50. Finder JD, Birnkrant D, Carl J, et al. American Thoracic Society. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004; 170: 456-65. Review.
51. A. Manzur, F. Muntoni, and A. Simonds Muscular dystrophy campaign sponsored workshop: recommendation for respiratory care of children with spinal muscular atrophy type II and III, 13th February 2002, London, UK Neuromuscul Disord 3 2003 184 189
52. C. Wallgren-Pettersson, K. Bushby, U. Mellie, A. Simonds, and E.N.M.C. 117th Workshop: ventilatory support in congenital neuromuscular disorders - congenital myopathies Congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4-6 April 2003, Naarden, The Netherlands. Neuromuscul Disord 14 2004 56 69
53. T. Munsat, and KE Davies International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscul Disord 2 1992 423 428
54. L. Merlini, E.S. Mazzone, A. Solari, and L. Morandi Reliability of hand-held dynamometry in spinal muscular atrophy Muscle Nerve 26 2002 64 70
55. L. Merlini, E. Bertini, and C. Minetti Motor function-muscle strength relationship in spinal muscular atrophy Muscle Nerve 29 2004 548 552
56. K. Zerres, and S. Rudnik-Schoneborn Natural history in proximal spinal muscular atrophy Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 52 1995 518 523
57. K. Zerres, S. Rudnik-Schoneborn, E. Forrest, A. Lusakowska, J. Borkowska, and I. Hausmanowa-Petrusewicz A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients J Neurol Sci 146 1997 67 72
58. S. Rudnik-Schoneborn, I. Hausmanowa-Petrusewicz, J. Borkowska, and K. Zerres The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III Eur Neurol 45 2001 174 181
59. F.J. Samaha, C.R. Buncher, and B.S. Russman Pulmonary function in spinal muscular atrophy J Child Neurol 9 1994 326 329